{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:40:27Z","timestamp":1784774427684,"version":"3.55.0"},"reference-count":76,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Primary aldosteronism (PA) is a group of disorders in which aldosterone is excessively produced. These disorders can lead to hypertension, hypokalemia, hypervolemia and metabolic alkalosis. The prevalence of PA ranges from 5% to 12% around the globe, and the most common causes are adrenal adenoma and adrenal hyperplasia. The importance of PA recognition arises from the fact that it can have a remarkably adverse cardiovascular and renal impact, which can even result in death. The aldosterone-to-renin ratio (ARR) is the election test for screening PA, and one of the confirmatory tests, such as oral sodium loading (OSL) or saline infusion test (SIT), is in general necessary to confirm the diagnosis. The distinction between adrenal hyperplasia (AH) or aldosterone-producing adenoma (APA) is essential to select the appropriate treatment. Therefore, in order to identify the subtype of PA, imaging exams such as computed tomography or magnetic ressonance imaging, and\/or invasive investigation such as adrenal catheterization must be performed. According to the subtype of PA, optimal treatment \u2013 surgical for APA or pharmacological for AH, with drugs like spironolactone and amiloride \u2013 must be offered.<\/jats:p>","DOI":"10.1515\/cclm-2017-0217","type":"journal-article","created":{"date-parts":[[2017,8,27]],"date-time":"2017-08-27T10:01:20Z","timestamp":1503828080000},"page":"360-372","source":"Crossref","is-referenced-by-count":26,"title":["Update in diagnosis and management of primary aldosteronism"],"prefix":"10.1515","volume":"56","author":[{"given":"Sofia M.","family":"Dick","sequence":"first","affiliation":[{"name":"Graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul (UFRGS) , Porto Alegre , RS, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Queiroz","sequence":"additional","affiliation":[{"name":"Graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul (UFRGS) , Porto Alegre , RS, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara L.","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul (UFRGS) , Porto Alegre , RS, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica","family":"Dall\u2019Agnol","sequence":"additional","affiliation":[{"name":"Graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul (UFRGS) , Porto Alegre , RS, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia A.","family":"Brondani","sequence":"additional","affiliation":[{"name":"Graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul (UFRGS) , Porto Alegre , RS, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"Silveiro","sequence":"additional","affiliation":[{"name":"Graduate Program in Medical Sciences: Endocrinology, Universidade Federal do Rio Grande do Sul (UFRGS) , Porto Alegre , RS, Brazil"},{"name":"Servi\u00e7o de Endocrinologia, Hospital de Cl\u00ednicas de Porto Alegre (HCPA) , Rua Ramiro Barcelos, 2350 \u2013 Pr\u00e9dio 12, 4\u00b0 andar , Porto Alegre , RS 90035-903, Brazil , Phone: +55.51.33598127"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2017,8,28]]},"reference":[{"key":"2021021223263545915_j_cclm-2017-0217_ref_001_w2aab3b7b8b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2016;101:1889\u2013916.","DOI":"10.1210\/jc.2015-4061"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_002_w2aab3b7b8b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Kucharz EJ. Micha\u0142 Lity\u0144ski, a forgotten author of the first description of primary hyperaldosteronism. Pol Arch Med Wewn 2007;117:57\u20138.","DOI":"10.20452\/pamw.79"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_003_w2aab3b7b8b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007;669:607\u201318.","DOI":"10.1111\/j.1365-2265.2007.02775.x"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_004_w2aab3b7b8b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Gordon RD, Stowasser MD, Tunny TJ, Klemm SA, Rutherford JC. High incidence in primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994;21:315\u20138.","DOI":"10.1111\/j.1440-1681.1994.tb02519.x"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_005_w2aab3b7b8b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young HF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000;85:2854\u20139.","DOI":"10.1210\/jc.85.8.2854"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_006_w2aab3b7b8b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293\u2013300.","DOI":"10.1016\/j.jacc.2006.07.059"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_007_w2aab3b7b8b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008;371:1921\u20136.","DOI":"10.1016\/S0140-6736(08)60834-X"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_008_w2aab3b7b8b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017;69:1811\u201320.","DOI":"10.1016\/j.jacc.2017.01.052"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_009_w2aab3b7b8b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"K\u00e4yser S, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab 2016;101:2826\u201335.","DOI":"10.1210\/jc.2016-1472"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_010_w2aab3b7b8b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Baguet JP, Steichen O, Mounier-V\u00e9hier C, Gosse P. SFE\/SFHTA\/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA? Ann Endocrinol (Paris) 2016;77:187\u201391.","DOI":"10.1016\/j.ando.2016.01.006"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_011_w2aab3b7b8b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013;62:331\u20136.","DOI":"10.1161\/HYPERTENSIONAHA.113.01060"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_012_w2aab3b7b8b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Kuo CC, Wu VC, Tsai CW, Wu KD. Relative kidney hyperfiltration in primary aldosteronism: a meta-analysis. J Renin Angiotensin Aldosterone Syst 2011;12:113\u201322.","DOI":"10.1177\/1470320310391331"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_013_w2aab3b7b8b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006;48:232\u20138.","DOI":"10.1161\/01.HYP.0000230444.01215.6a"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_014_w2aab3b7b8b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Schirpenbach C, Reincke M. Primary aldosteronism: current knowledge and controversies in Conn\u2019s syndrome. Nat Clin Pract Endocrinol Metab 2007;3:220\u20137.","DOI":"10.1038\/ncpendmet0430"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_015_w2aab3b7b8b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"\u00c5kerstr\u00f6m T, Maharjan R, Willenberg HS, Cupisti K, Ip J, Moser A, et al. Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci Rep 2016;6:19546.","DOI":"10.1038\/srep19546"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_016_w2aab3b7b8b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011;58:797\u2013803.","DOI":"10.1161\/HYPERTENSIONAHA.111.175083"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_017_w2aab3b7b8b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Pech\u00e8re-Bertschi A, Herpin D, Lefebvre H. SFE\/SFHTA\/AFCE consensus on primary aldosteronism, part 7: medical treatment of primary aldosteronism. Ann Endocrinol (Paris) 2016;77:226\u201334.","DOI":"10.1016\/j.ando.2016.01.010"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_018_w2aab3b7b8b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243\u20138.","DOI":"10.1016\/j.jacc.2005.01.015"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_019_w2aab3b7b8b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Seccia TM, Caroccia B, Adler GK, Maiolino G, Cesari M, Rossi GP. Arterial hypertension, atrial fibrillation, and hyperaldosteronism: the triple trouble. Hypertension 2017;69:545\u201350.","DOI":"10.1161\/HYPERTENSIONAHA.116.08956"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_020_w2aab3b7b8b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011;29:980\u201390.","DOI":"10.1097\/HJH.0b013e3283455ca5"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_021_w2aab3b7b8b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594\u20137.","DOI":"10.1161\/01.CIR.101.6.594"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_022_w2aab3b7b8b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Farquharson CA, Struthers AD. Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart 2002;88:475\u201380.","DOI":"10.1136\/heart.88.5.475"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_023_w2aab3b7b8b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary aldosteronism. Br J Surg 2002;89:1587\u201393.","DOI":"10.1046\/j.1365-2168.2002.02261.x"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_024_w2aab3b7b8b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Harvey AM. Hyperaldosteronism: diagnosis, lateralization, and treatment. Surg Clin N Am 2014;94:643\u201356.","DOI":"10.1016\/j.suc.2014.02.007"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_025_w2aab3b7b8b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Kumar B, Swee M. Aldosterone-renin ratio in the assessment of primary aldosteronism. J Am Med Assoc 2014;312:184\u20135.","DOI":"10.1001\/jama.2014.64"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_026_w2aab3b7b8b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Lonati C, Bassani N, Gritti A, Biganzoli E, Morganti A. Measurement of plasma renin concentration instead of plasma renin activity decreases the positive aldosterone-to-renin ratio tests in treated patients with essential hypertension. J Hypertens 2014;32:627\u201334.","DOI":"10.1097\/HJH.0000000000000076"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_027_w2aab3b7b8b1b6b1ab2b1c27Aa","unstructured":"Stowasser P, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD. Laboratory investigation of primary aldosteronism. Clin Biochem Rev 2010;31:39\u201356."},{"key":"2021021223263545915_j_cclm-2017-0217_ref_028_w2aab3b7b8b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Juutilainen A, Savolainen K, Romppanen J, Turpeinen U, H\u00e4m\u00e4l\u00e4inen E, Kemppainen J, et al. Combination of LC-MS\/MS aldosterone and automated direct renin in screening for primary aldosteronism. Clin Chim Acta 2014;433:209\u201315.","DOI":"10.1016\/j.cca.2014.03.015"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_029_w2aab3b7b8b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Rehan M, Raizman JE, Cavalier E, Don-Wauchope AC, Holmes DT. Laboratory challenges in primary aldosteronism screening and diagnosis. Clin Biochem 2015;48:377\u201387.","DOI":"10.1016\/j.clinbiochem.2015.01.003"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_030_w2aab3b7b8b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Rossi GP, Bisogni V. A useful tool to improve the case detection rate of primary aldosteronism: the aldosterone-renin ratio (ARR)-App. J Hypertens 2016;34:1019\u201321.","DOI":"10.1097\/HJH.0000000000000892"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_031_w2aab3b7b8b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Galati SJ. Primary aldosteronism challenges in diagnosis and management. Endocrinol Metab Clin N Am 2015;44:355\u201369.","DOI":"10.1016\/j.ecl.2015.02.010"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_032_w2aab3b7b8b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004;22:377\u201381.","DOI":"10.1097\/00004872-200402000-00023"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_033_w2aab3b7b8b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Durango N, Fuentes CA, Castillo AE, Gonz\u00e1lez-G\u00f3mez LM, Vecchiola A, Fardella CE, et al. Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension. Int J Mol Sci 2016;17:797.","DOI":"10.3390\/ijms17070797"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_034_w2aab3b7b8b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Sp\u00e4t A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004;84:489\u2013539.","DOI":"10.1152\/physrev.00030.2003"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_035_w2aab3b7b8b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Stabler TV, Siegel AL. Chemiluminescence immunoassay of aldosterone in serum. Clin Chem 1991;37:1987\u20139.","DOI":"10.1093\/clinchem\/37.11.1987"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_036_w2aab3b7b8b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Mayes D, Furuyama S, Kem DC, Nugent CA. A radioimmunoassay for plasma aldosterone. J Clin Endocrinol Metab 1970;30:682\u20135.","DOI":"10.1210\/jcem-30-5-682"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_037_w2aab3b7b8b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Wedatilake YN, Scanlon MJ, Barnes SC. The clinical utility of two renin mass methods to detect primary hyperaldosteronism compared with renin activity. Ann Clin Biochem 2011;48:256\u201362.","DOI":"10.1258\/acb.2010.010171"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_038_w2aab3b7b8b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Manolopoulou J, Fischer E, Dietz A, Diederich S, Holmes D, Junnila R, et al. Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. J Hypertens 2015;33:2500\u201311.","DOI":"10.1097\/HJH.0000000000000727"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_039_w2aab3b7b8b1b6b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Rossi GP, Ceolotto G, Rossitto G, Seccia TM, Maiolino G, Berton C, et al. Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clin Chem Lab Med 2016;54:1441\u201350.","DOI":"10.1515\/cclm-2015-1094"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_040_w2aab3b7b8b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M. Effect of contraceptives on aldosterone\/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab 2011;96:1797\u2013804.","DOI":"10.1210\/jc.2010-2918"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_041_w2aab3b7b8b1b6b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"Aronova A, Fahey III TJ, Zarnegar R. Management of hypertension in primary aldosteronism. World J Cardiol 2014;6:227\u201333.","DOI":"10.4330\/wjc.v6.i5.227"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_042_w2aab3b7b8b1b6b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"Yin G, Zhang S, Yan L, Wu M, Xu M, Li F, et al. One-hour upright posture is an ideal position for serum aldosterone concentration and plasma renin activity measuring on primary aldosteronism screening. Exp Clin Endocrinol Diabetes 2012;120:388\u201394.","DOI":"10.1055\/s-0032-1301894"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_043_w2aab3b7b8b1b6b1ab2b1c43Aa","doi-asserted-by":"crossref","unstructured":"Barigou M, Ah-Kang F, Orloff E, Amar J, Chamontin B, Bouhanick B. Effect of postural changes on aldosterone to plasma renin ratio in patients with suspected secondary hypertension. Ann Cardiol Angeiol (Paris) 2015;64:169\u201374.","DOI":"10.1016\/j.ancard.2015.04.017"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_044_w2aab3b7b8b1b6b1ab2b1c44Aa","doi-asserted-by":"crossref","unstructured":"Reznik Y, Amar L, Tabarin A. SFE\/SFHTA\/AFCE consensus on primary aldosteronism, part 3: confirmatory testing. Ann Endocrinol (Paris) 2016;77:202\u20137.","DOI":"10.1016\/j.ando.2016.01.007"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_045_w2aab3b7b8b1b6b1ab2b1c45Aa","doi-asserted-by":"crossref","unstructured":"Ahmed AH, Cowley D, Wolley M, Gordon RD, Xu S, Taylor PJ, et al. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab 2014;99:2745\u201353.","DOI":"10.1210\/jc.2014-1153"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_046_w2aab3b7b8b1b6b1ab2b1c46Aa","doi-asserted-by":"crossref","unstructured":"Nanba K, Tamanaha T, Nakao K, Kawashima ST, Usui T, Tagami T, et al. Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab 2012;97:1688\u201394.","DOI":"10.1210\/jc.2011-2504"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_047_w2aab3b7b8b1b6b1ab2b1c47Aa","doi-asserted-by":"crossref","unstructured":"Rossi GP, Seccia TM, Pessina AC. A diagnostic algorithm-the holy grail of primary aldosteronism. Nat Rev Endocrinol 2011;7:697\u20139.","DOI":"10.1038\/nrendo.2011.180"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_048_w2aab3b7b8b1b6b1ab2b1c48Aa","unstructured":"Gordon RD, Gomez-Sanchez CE, Hamlet SM, Tunny TJ, Klemm SA. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. J Hypertens Suppl 1987;5:S103\u20136."},{"key":"2021021223263545915_j_cclm-2017-0217_ref_049_w2aab3b7b8b1b6b1ab2b1c49Aa","doi-asserted-by":"crossref","unstructured":"Phillips JL, Walther MM, Pezzullo JC, Rayford W, Choyke PL, Berman AA, et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000;85:4526\u201333.","DOI":"10.1210\/jcem.85.12.7086"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_050_w2aab3b7b8b1b6b1ab2b1c50Aa","doi-asserted-by":"crossref","unstructured":"Bardet S, Chamontin B, Douillard C, Pagny JY, Hernigou A, Joffre F, et al. SFE\/SFHTA\/AFCE consensus on primary aldosteronism, part 4: subtype diagnosis. Ann Endocrinol (Paris) 2016;77:208\u201313.","DOI":"10.1016\/j.ando.2016.01.008"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_051_w2aab3b7b8b1b6b1ab2b1c51Aa","doi-asserted-by":"crossref","unstructured":"Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension 2014;63:151\u201360.","DOI":"10.1161\/HYPERTENSIONAHA.113.02097"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_052_w2aab3b7b8b1b6b1ab2b1c52Aa","doi-asserted-by":"crossref","unstructured":"Monticone S, Viola A, Rossato D, Veglio F, Reincke M, Gomez-Sanchez C, et al. Adrenal vein sampling in primary aldosteronism: towards a standardized protocol. Lancet Diabet Endocrinol 2015;3:296\u2013303.","DOI":"10.1016\/S2213-8587(14)70069-5"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_053_w2aab3b7b8b1b6b1ab2b1c53Aa","doi-asserted-by":"crossref","unstructured":"Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009;151:329\u201337.","DOI":"10.7326\/0003-4819-151-5-200909010-00007"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_054_w2aab3b7b8b1b6b1ab2b1c54Aa","doi-asserted-by":"crossref","unstructured":"Lim V, Guo Q, Grant CS, Thompson GB, Richards ML, Farley DR, et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab 2014;99:2712\u20139.","DOI":"10.1210\/jc.2013-4146"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_055_w2aab3b7b8b1b6b1ab2b1c55Aa","doi-asserted-by":"crossref","unstructured":"Ladurner R, Sommerey S, Buechner S, Dietz A, Degenhart C, Hallfeldt K, et al. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism. Eur J Clin Invest 2017;47:372\u20137.","DOI":"10.1111\/eci.12746"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_056_w2aab3b7b8b1b6b1ab2b1c56Aa","doi-asserted-by":"crossref","unstructured":"Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, et al. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens 2007;25:1433\u201342.","DOI":"10.1097\/HJH.0b013e328126856e"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_057_w2aab3b7b8b1b6b1ab2b1c57Aa","doi-asserted-by":"crossref","unstructured":"Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, et al. The adrenal vein sampling international study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab 2012;97:1606\u201314.","DOI":"10.1210\/jc.2011-2830"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_058_w2aab3b7b8b1b6b1ab2b1c58Aa","doi-asserted-by":"crossref","unstructured":"Rossitto G, Miotto D, Battistel M, Barbiero G, Maiolino G, Bisogni V, et al. Metoclopramide unmasks potentially misleading contralateral suppression in patients undergoing adrenal vein sampling for primary aldosteronism. J Hypertens 2016;34:2258\u201365.","DOI":"10.1097\/HJH.0000000000001082"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_059_w2aab3b7b8b1b6b1ab2b1c59Aa","doi-asserted-by":"crossref","unstructured":"Mulatero P, Bertello C, Sukor N, Gordon R, Rossato D, Daunt N, et al. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. Hypertension 2010;55:667\u201373.","DOI":"10.1161\/HYPERTENSIONAHA.109.146613"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_060_w2aab3b7b8b1b6b1ab2b1c60Aa","doi-asserted-by":"crossref","unstructured":"Seccia TM, Miotto D, Battistel M, Motta R, Barisa M, Maniero C, et al. A stress reaction affects assessment of selectivity of adrenal venous sampling and of lateralization of aldosterone excess in primary aldosteronism. Eur J Endocrinol 2012;166:869\u201375.","DOI":"10.1530\/EJE-11-0972"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_061_w2aab3b7b8b1b6b1ab2b1c61Aa","doi-asserted-by":"crossref","unstructured":"Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001;86:1083\u201390.","DOI":"10.1210\/jcem.86.3.7287"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_062_w2aab3b7b8b1b6b1ab2b1c62Aa","doi-asserted-by":"crossref","unstructured":"Rossi GP, Pitter G, Bernante P, Motta R, Feltrin G, Miotto D. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens 2008;26:989\u201397.","DOI":"10.1097\/HJH.0b013e3282f9e66a"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_063_w2aab3b7b8b1b6b1ab2b1c63Aa","doi-asserted-by":"crossref","unstructured":"Umakoshi H, Naruse M, Wada N, Ichijo T, Kamemura K, Matsuda Y, et al. Adrenal venous sampling in patients with positive screening but negative confirmatory testing for primary aldosteronism. Hypertension 2016;67:1014\u20139.","DOI":"10.1161\/HYPERTENSIONAHA.115.06607"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_064_w2aab3b7b8b1b6b1ab2b1c64Aa","doi-asserted-by":"crossref","unstructured":"Wolley MJ, Gordon RD, Ahmed AH, Stowasser M. Does contralateral suppression at adrenal venous sampling predict outcome following unilateral adrenalectomy for primary aldosteronism? A retrospective study. J Clin Endocrinol Metab 2015;100:1477\u201384.","DOI":"10.1210\/jc.2014-3676"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_065_w2aab3b7b8b1b6b1ab2b1c65Aa","doi-asserted-by":"crossref","unstructured":"Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266\u201381.","DOI":"10.1210\/jc.2008-0104"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_066_w2aab3b7b8b1b6b1ab2b1c66Aa","doi-asserted-by":"crossref","unstructured":"Deinum J, Riksen NP, Lenders JW. Pharmacological treatment of aldosterone excess. Pharmacol Ther 2015;154:120\u201333.","DOI":"10.1016\/j.pharmthera.2015.07.006"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_067_w2aab3b7b8b1b6b1ab2b1c67Aa","doi-asserted-by":"crossref","unstructured":"Steichen O, Lorthioir A, Zinzindohoue F, Plouin PF, Amar L. Outcomes of drug-based and surgical treatments for primary aldosteronism. Adv Chronic Kidney Dis 2015;22:196\u2013203.","DOI":"10.1053\/j.ackd.2014.10.003"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_068_w2aab3b7b8b1b6b1ab2b1c68Aa","doi-asserted-by":"crossref","unstructured":"Rossi GP. Diagnosis and treatment of primary aldosteronism. Rev Endocr Metab Disord 2011;12:27\u201336.","DOI":"10.1007\/s11154-011-9162-8"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_069_w2aab3b7b8b1b6b1ab2b1c69Aa","doi-asserted-by":"crossref","unstructured":"Gromotowicz-Poplawska A, Szoka P, Kolodziejczyk P, Kramkowski K, Wojewodzka-Zelezniakowicz M, Chabielska E. New agents modulating the renin-angiotensin-aldosterone system\u2014will there be a new therapeutic option? Exp Biol Med (Maywood) 2016;241:1888\u201399.","DOI":"10.1177\/1535370216660211"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_070_w2aab3b7b8b1b6b1ab2b1c70Aa","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016;175:G1\u201334.","DOI":"10.1530\/EJE-16-0467"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_071_w2aab3b7b8b1b6b1ab2b1c71Aa","doi-asserted-by":"crossref","unstructured":"Celen O, O\u2019Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg 1996;131:646\u201350.","DOI":"10.1001\/archsurg.1996.01430180072015"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_072_w2aab3b7b8b1b6b1ab2b1c72Aa","doi-asserted-by":"crossref","unstructured":"Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001;135:258\u201361.","DOI":"10.7326\/0003-4819-135-4-200108210-00010"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_073_w2aab3b7b8b1b6b1ab2b1c73Aa","doi-asserted-by":"crossref","unstructured":"Letavernier E, Peyrard S, Amar L, Zinzindohou\u00e9 F, Fiquet B, Plouin PF. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 2008;26:1816\u201323.","DOI":"10.1097\/HJH.0b013e3283060f0c"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_074_w2aab3b7b8b1b6b1ab2b1c74Aa","doi-asserted-by":"crossref","unstructured":"Meyer A, Brabant G, Behrend M. Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg 2005;29:155\u20139.","DOI":"10.1007\/s00268-004-7496-z"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_075_w2aab3b7b8b1b6b1ab2b1c75Aa","doi-asserted-by":"crossref","unstructured":"Catena C, Colussi GL, Di Fabio A, Sechi LA. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res 2010;42:440\u20135.","DOI":"10.1055\/s-0029-1246185"},{"key":"2021021223263545915_j_cclm-2017-0217_ref_076_w2aab3b7b8b1b6b1ab2b1c76Aa","doi-asserted-by":"crossref","unstructured":"Wang W, Hu W, Zhang X, Wang B, Bin C, Huang H. Predictors of successful outcome after adrenalectomy for primary aldosteronism. Int Surg 2012;97:104\u201311.","DOI":"10.9738\/CC140.1"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2018.56.issue-3\/cclm-2017-0217\/cclm-2017-0217.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0217\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0217\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:57:48Z","timestamp":1619049468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0217\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,28]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,8,28]]},"published-print":{"date-parts":[[2018,2,23]]}},"alternative-id":["10.1515\/cclm-2017-0217"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2017-0217","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8,28]]}}}